DexCom Cash Flow Statement
NASDAQ: DXCMHealth CareMedical/Dental InstrumentsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
DexCom free cash flow
In fiscal 2025, DexCom generated $1.44 billion of operating cash flow and spent $363.5 million on capital expenditures. That left free cash flow of $1.08 billion, a free-cash-flow margin of 23.1% of revenue. Free cash flow was up 70.8% from the prior year's $630.7 million.
DexCom returned $500.0 million to shareholders through share repurchases, equal to 46% of free cash flow.
Summary generated from market data by MetaCap's automated system. Methodology
DexCom cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | 836.30M | 576.20M | 541.50M | 341.20M | 216.90M | 549.70M | 101.10M | -127.10M | -50.20M | -65.60M |
| Net Income growth (YoY) | +45.14% | +6.41% | +58.70% | +57.31% | -60.54% | +443.72% | — | — | — | — |
| Depreciation & Amortization | 251.80M | 217.70M | 186.00M | 155.90M | 102.00M | 67.10M | 48.70M | 29.10M | 16.10M | 15.00M |
| Stock-Based Compensation | 159.60M | 170.40M | 150.80M | 126.50M | 113.40M | 119.40M | 102.70M | 101.90M | 106.20M | 110.80M |
| Change in Working Capital | 66.60M | 183.30M | -26.90M | 12.90M | -151.00M | -64.70M | -7.30M | -65.50M | -14.80M | -19.70M |
| Operating Cash Flow | 1.44B | 989.50M | 748.50M | 669.50M | 442.50M | 475.60M | 314.50M | 123.20M | 92.00M | 56.20M |
| Capital Expenditures | -363.50M | -358.80M | -236.60M | -364.80M | -389.20M | -199.00M | -180.00M | -67.10M | -66.00M | -55.70M |
| Investing Cash Flow | 536.00M | -207.50M | -507.20M | -521.50M | -216.10M | -1.02B | -1.02B | -139.80M | -144.40M | -55.90M |
| Share Repurchases | -500.00M | -750.00M | -688.70M | -557.70M | 0 | 0 | 0 | -100.00M | 0 | 0 |
| Debt Repaid | — | — | — | — | — | — | — | — | 0 | -2.30M |
| Financing Cash Flow | -1.69B | -734.80M | -318.60M | -552.50M | 10.40M | 912.10M | 10.70M | 710.40M | 399.10M | 8.10M |
| Net Change in Cash | 311.80M | 39.80M | -75.80M | -410.30M | 235.40M | 371.80M | -690.70M | 695.60M | 347.00M | 8.40M |
| Free Cash Flow | 1.08B | 630.70M | 511.90M | 304.70M | 53.30M | 276.60M | 134.50M | 56.10M | 26.00M | 500.00K |
This table shows 10 annual periods of DexCom's cash flow statement, from FY 2025 back to FY 2016, across 13 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow DXCM's reporting calendar. What is a cash flow statement?